By Matt McCallMar 13, 2019
I’m packing my bags and getting ready to head to my second cannabis conference of the year. If it’s anything like the first one, the buzz will be about the next big domino expected to fall in the wave of legalization.
A big part of my job is hitting the road and staying in contact with industry insiders and executives to help my readers get to the biggest investment opportunities first. There’s no substitute for face-to-face conversations, whether they are arranged meetings, impromptu visits in the hallways, or happen over a cup of coffee.
That’s what I did a little over a month ago in Miami, and now I’m heading to Indianapolis. I’ve been following the huge opportunities in marijuana companies for nearly a decade, but when I left the last conference, my enthusiasm for the long-term wealth-building potential was at a new level.
When it comes to legal marijuana, Canada certainly has the “first mover advantage.” But I’m seeing more opportunity here in the United States.
Having passed full legalization last fall, Canada is projected to be a $5.9 billion market for legal cannabis by 2022.
That’s about where the U.S. market was in 2015.
And that was when only four states, plus D.C., had full legalization.
Now we’re up to 11 states when you include Alaska. (And many more allow medicinal use.)
By 2017, the U.S. legal marijuana market had exploded 57.4% to reach $8.5 billion.
Numbers are useless without perspective, so here you go: That was more money than was spent on ice cream!
By 2018, we were at $10.4 billion. And according to Arcview Market Research and BDS Analytics, we’ll easily keep up that pace through 2022 – when U.S. spending will reach $22.2 billion.
That’ll be nearly four times the size of Canada’s marijuana market.
I recently told my Investment Opportunities readers about a huge potential catalyst on the horizon. It’s called the STATES Act.
STATES is short for Strengthening the Tenth Amendment Through Entrusting States. The Act is a bipartisan bill put together by Senators Cory Gardner (R-CO) and Elizabeth Warren (D-MA). The legislation was introduced last June. If passed, it would amend the Controlled Substances Act.
This is big because the federal prohibition would be eliminated in states that legalize marijuana. As long as residents follow their state’s laws on marijuana, the federal government would not be able to intervene.
The odds of the bill getting passed this year are very high. It would make it even easier for more states to legalize marijuana. More importantly, it would be the first major step to federal legalization… and that’s when the opportunity opens up all the way.
Harvest Health & Recreation (OTC:HRVSF) has picked up on the trend of already increasing sales and the potential for explosive growth. The Arizona-based cannabis grower and retailer went public on the Canadian Securities Exchange last November — and it’s also trading on the OTC market in the United States under the symbol HRVSF.
From its home base in Phoenix, Harvest Health has already spread to eight other states (within just six years). And on Monday, it announced a merger with Verano Holdings – in which the combined company will own licenses for up to 200 facilities, across 16 states.
The buyout comes with a steep price tag: $850 million (U.S. dollars). That’s the biggest marijuana merger since the $835 million deal between iAnthus Capital (ITHUF) and MPX Bioceuticals in October.
Taken together, that’s $1.5 billion in just two corporate mergers. You think they don’t see opportunity?
Harvest may have inked the bigger deal, but I actually prefer iAnthus as an investment.
iAnthus owns and operates cannabis cultivators, processors, and dispensaries in the U.S. Now that it has merged with MPX, it has operations in 11 states, more than 60 retail locations, and over 500,000 square feet of cultivation and processing space.
I saw huge upside potential in iAnthus going back to last year. It’s up nearly 30% just in 2019 alone, and management said this will be a “transformative year” for the company. I couldn’t agree more. As the integration of iAnthus and MPX progresses, it will lead to impressive financials as the U.S. opportunity continues to grow.
Based on 2020 revenue expectations of $336 million, iAnthus trades with an Enterprise Value/Revenue ratio of 1.15. This is the lowest of all the major U.S. marijuana companies. Even more impressive is that iAnthus is expected to be one of the first companies in the industry to turn a meaningful profit.
Based on 2020 earnings estimates, the stock trades with a price-to-earnings (P/E) ratio of 17.9. With the kind of growth prospects I’ve outlined here, that makes iAnthus a phenomenal bargain.
P.S. The opportunity in legal weed is much like the opportunity internet stocks offered in 1994… or that bitcoin offered in 2015. The business is set to grow so much over the next 10 years that I believe it will turn out to be one of the three biggest investment opportunities of your entire life, no matter when you were born.
That’s why I recommend multiple ways to make money in my Investment Opportunities service. And it’s why our marijuana stocks are up an average of 48% in just the first 10 weeks of 2019.
Even if you don’t know a thing about the marijuana market… even if you’ve never bought a stock before. If you have just a small stake, you could make a lot of money over the next 12 months. Click here to learn more about this incredible story.
Don't miss out on the incredible megatrends that are shaping today's market. Gain access to the most powerful market insights and stock advice from Matt McCall absolutely FREE. Join Today!